CDF IMAGES

  • Portfolio
    • All Galleries
    • Search
    • Cart
    • Lightbox
    • Client Area
  • Services
    • Commercial and Event Photography
    • Portrait Photography
    • Product Catalogue
    • General Terms and Conditions
    • Commercial Terms and Conditions of Business
  • About
  • Contact
  • Facebook
  • Twitter
x
All Galleries
Add to Cart
twitterlinkedinfacebook

COVID-19 vaccine through partnerships with pharmaceutical company Valneva, Livingston, 21 July 2020 23 images Created 21 Jul 2020

Livingston, Scotland, UK. 21 July 2020
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.

Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
View: 100 | All

Loading ()...

  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5294.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5295.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5297.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5298.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5300.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5303.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5302.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5304.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5305.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5306.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5307.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5309.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5310.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5312.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5311.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7349.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7354.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7358.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7360.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7361.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7363.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7368.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7367.jpg